StreetInsider.com News Articles

Recursion Pharmaceuticals (RXRX) PT Raised to $5.90 at Morgan Stanley

Fri, 16 Oct 2026 08:43:27 -0400

Morgan Stanley analyst Sean Laaman raised the price target on Recursion Pharmaceuticals (NASDAQ: RXRX) to $5.90 (from $5.30) while maintaining a Equalweight rating.

Form 424B5 RECURSION PHARMACEUTICAL

Thu, 15 Oct 2026 17:31:00 -0400

si-local-file:///var/storage/secattach/20261015/27194295.html

Form 8-K RECURSION PHARMACEUTICAL For: Oct 15

Thu, 15 Oct 2026 08:47:00 -0400

si-local-file:///var/storage/secattach/20261015/27190454.html

Sanofi options Recursion drug candidate, triggering $10M payment

Thu, 15 Oct 2026 08:46:05 -0400

Sanofi has exercised an option on a development candidate from its ongoing research collaboration with Recursion Pharmaceuticals (NASDAQ: RXRX), according to a press release from Recursion dated Oct. 15, 2026.

The option exercise triggered a $10 million milestone payment to Recursion, bringing total upfront and milestone payments received under the collaboration to $144 million. Recursion said it remains eligible for more than $300 million in additional milestone payments under the program, along with low double-digit royalties on net product sales if the candidate is approved and commercialized.

The $10 million payment will be recognized as revenue in Recursion's third quarter of 2026.

Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration

Thu, 15 Oct 2026 08:45:00 -0400

The option triggered a $10 million milestone payment to Recursion, bringing total upfront and milestone payments received from Sanofi under the collaboration to $144 million; Recursion is eligible for more than $300 million in additional milestones under the program, with double

Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration

Thu, 15 Oct 2026 08:45:00 -0400

Recursion prices $200M stock offering at $3.25 per share

Thu, 15 Oct 2026 08:31:05 -0400

Recursion Pharmaceuticals (NASDAQ: RXRX) priced an underwritten public offering of 61,540,000 shares of its Class A common stock at $3.25 per share, according to a press release issued Oct. 15, 2026.

The Salt Lake City-based clinical-stage company expects to receive gross proceeds of approximately $200 million before underwriting discounts, commissions, and estimated offering expenses. All shares are being sold by Recursion. The offering was expected to close on or about Oct. 16, 2026, subject to customary closing conditions.

Participating investors in the offering include Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, and Driehaus Capital Management, among other institutional and healthcare-focused funds.

Leerink

Recursion prices $200M stock offering at $3.25 per share

Thu, 15 Oct 2026 08:31:05 -0400

Recursion Pharmaceuticals (NASDAQ: RXRX) priced an underwritten public offering of 61,540,000 shares of its Class A common stock at $3.25 per share, according to a press release issued Oct. 15, 2026.

Leerink

Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock

Thu, 15 Oct 2026 08:30:00 -0400

Salt Lake City, UT, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, today announced the pricing of an underwritten offering of 61,540,000 shares of its Class A common stock at a price of $3.25 per share. All of the shares are to be sold by Recursion. Before deducting the underwriting discounts and commissions and estimated offering expenses, Recursion expects to receive total gross proceeds of approximately $200 million. The offering is expected to close on

Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock

Thu, 15 Oct 2026 08:30:00 -0400

Recursion raises $200M, reports clinical updates and Sanofi milestone

Thu, 15 Oct 2026 08:23:09 -0400

Recursion Pharmaceuticals (Nasdaq: RXRX) has completed a $200 million oversubscribed underwritten common stock offering, with investors including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, and Driehaus Capital Management, according to a company statement.

The financing extends Recursion's expected cash runway into 2029. As of September 30, 2026, the company held approximately $561 million in cash, cash equivalents, and restricted cash, a figure described as preliminary and unaudited.

Recursion also released updated clinical data for two pipeline candidates. In its Phase 1b/2 TUPELO study of REC-4881 in Familial Adenomatous Polyposis (FAP), the drug showed a 47% median reduction in total polyp burden

Recursion raises $200M, reports clinical updates and Sanofi milestone

Thu, 15 Oct 2026 08:23:09 -0400

Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone

Thu, 15 Oct 2026 08:22:00 -0400

Leading Healthcare Investors, including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital Management and other prominent healthcare specialists and mutual funds invest $200 million in Recursion
REC-4881 (MEK1/2 inhibitor) Phase 1b/2 Data Update: Deep, durable polyp burden reductions reproduced in the expanded adult FAP population (18+), with a 47% median reduction after 12 weeks of treatment and 85% of patients maintaining reductions below baseline after 12 weeks off treatment. New upper GI data, addressing the area of greatest unmet medical need in FAP, show a 55% median polyp burden reduction, including two patients with ≥98% polyp burden reduction, and

Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone

Thu, 15 Oct 2026 08:22:00 -0400

Leading Healthcare Investors, including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital Management and other prominent healthcare specialists and mutual funds invest $200 million in Recursion
REC-4881 (MEK1/2 inhibitor) Phase 1b/2 Data Update: Deep, durable polyp burden reductions reproduced in the expanded adult FAP population (18+), with a 47% median reduction after 12 weeks of treatment and 85% of patients maintaining reductions below baseline after 12 weeks off treatment. New upper GI data, addressing the area of greatest unmet medical need in FAP, show a 55% median polyp burden reduction, including two patients with ≥98% polyp burden reduction, and

Form 424B5 RECURSION PHARMACEUTICAL

Thu, 15 Oct 2026 08:20:00 -0400
si-local-file:///var/storage/secattach/20261015/27190150.html

FTC seeks contempt finding against Martin Shkreli for alleged pharma ban violation

Tue, 13 Oct 2026 08:54:03 -0400

Investing.com -- The Federal Trade Commission and seven states are seeking to hold Martin Shkreli in contempt of court, alleging that the former pharmaceutical executive violated a lifetime ban on participating in the drug industry.

The motion, as described in the draft, centers on Shkreli’s alleged trading in pharmaceutical stocks and online commentary about biotech investments. Regulators contend that his activities violate a 2022 court order barring him from the pharmaceutical industry.

According to the allegations, Shkreli traded shares in at least 60 pharmaceutical companies and used livestreams on YouTube, X and Reddit to discuss trading strategies and short-selling campaigns. In

FTC seeks contempt finding against Martin Shkreli for alleged pharma ban violation

Tue, 13 Oct 2026 08:54:03 -0400

Investing.com -- The Federal Trade Commission and seven states are seeking to hold Martin Shkreli in contempt of court, alleging that the former pharmaceutical executive violated a lifetime ban on participating in the drug industry.

The motion, as described in the draft, centers on Shkreli’s alleged trading in pharmaceutical stocks and online commentary about biotech investments. Regulators contend that his activities violate a 2022 court order barring him from the pharmaceutical industry.

According to the allegations, Shkreli traded shares in at least 60 pharmaceutical companies and used livestreams on YouTube, X and Reddit to discuss trading strategies and short-selling campaigns. In

FTC seeks contempt finding against Martin Shkreli for alleged pharma ban violation

Tue, 13 Oct 2026 08:54:03 -0400

Investing.com -- The Federal Trade Commission and seven states are seeking to hold Martin Shkreli in contempt of court, alleging that the former pharmaceutical executive violated a lifetime ban on participating in the drug industry.

The motion, as described in the draft, centers on Shkreli’s alleged trading in pharmaceutical stocks and online commentary about biotech investments. Regulators contend that his activities violate a 2022 court order barring him from the pharmaceutical industry.

According to the allegations, Shkreli traded shares in at least 60 pharmaceutical companies and used livestreams on YouTube, X and Reddit to discuss trading strategies and short-selling campaigns. In

FTC seeks contempt finding against Martin Shkreli for alleged pharma ban violation

Tue, 13 Oct 2026 08:54:03 -0400

Investing.com -- The Federal Trade Commission and seven states are seeking to hold Martin Shkreli in contempt of court, alleging that the former pharmaceutical executive violated a lifetime ban on participating in the drug industry.

The motion, as described in the draft, centers on Shkreli’s alleged trading in pharmaceutical stocks and online commentary about biotech investments. Regulators contend that his activities violate a 2022 court order barring him from the pharmaceutical industry.

According to the allegations, Shkreli traded shares in at least 60 pharmaceutical companies and used livestreams on YouTube, X and Reddit to discuss trading strategies and short-selling campaigns. In

Form 4 RECURSION PHARMACEUTICAL For: Oct 06 Filed by: Borgeson Blake

Wed, 07 Oct 2026 18:09:00 -0400
si-local-file:///var/storage/secattach/20261007/27162154.html

Form 4 RECURSION PHARMACEUTICAL For: Oct 06 Filed by: HERSHBERG ROBERT

Wed, 07 Oct 2026 18:08:00 -0400
si-local-file:///var/storage/secattach/20261007/27162152.html

Form 144 RECURSION PHARMACEUTICAL Filed by: Borgeson Blake

Tue, 06 Oct 2026 11:48:00 -0400
si-local-file:///var/storage/secattach/20261006/27154235.html

Form 144 RECURSION PHARMACEUTICAL Filed by: HERSHBERG ROBERT

Tue, 06 Oct 2026 11:09:00 -0400
si-local-file:///var/storage/secattach/20261006/27154049.html

Form 4 RECURSION PHARMACEUTICAL For: Oct 01 Filed by: Dar Zavain

Fri, 02 Oct 2026 18:18:00 -0400
si-local-file:///var/storage/secattach/20261002/27143879.html

Form 4 RECURSION PHARMACEUTICAL For: Oct 01 Filed by: Li Dean Y

Fri, 02 Oct 2026 18:17:00 -0400
si-local-file:///var/storage/secattach/20261002/27143876.html